Omnicell (NASDAQ:OMCL) Price Target Raised to $58.00

Omnicell (NASDAQ:OMCL - Free Report) had its target price increased by Barclays from $39.00 to $58.00 in a research report report published on Thursday, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Other equities research analysts also recently issued reports about the stock. StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Saturday, October 19th. Craig Hallum lifted their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a research note on Thursday. Benchmark reiterated a "buy" rating and set a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Wells Fargo & Company lifted their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a research note on Monday, October 14th. Finally, Bank of America reiterated a "neutral" rating and set a $57.00 price target (up from $44.00) on shares of Omnicell in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Omnicell currently has a consensus rating of "Hold" and an average price target of $49.14.

Omnicell Stock Down 8.3 %

Shares of NASDAQ:OMCL traded down $4.41 during trading hours on Thursday, reaching $48.64. The stock had a trading volume of 1,061,254 shares, compared to its average volume of 527,409. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74. The firm's 50 day moving average is $43.26 and its 200-day moving average is $35.17. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -124.72, a P/E/G ratio of 43.55 and a beta of 0.83.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. During the same period in the prior year, the firm posted $0.29 EPS. The company's quarterly revenue was down 7.4% compared to the same quarter last year. Research analysts predict that Omnicell will post 0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its position in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock worth $55,000 after purchasing an additional 553 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company's stock worth $38,000 after purchasing an additional 1,000 shares during the last quarter. 1620 Investment Advisors Inc. grew its position in Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock worth $96,000 after purchasing an additional 1,542 shares during the last quarter. EntryPoint Capital LLC grew its position in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company's stock worth $72,000 after purchasing an additional 1,345 shares during the last quarter. Finally, CWM LLC grew its position in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company's stock worth $83,000 after purchasing an additional 1,236 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.